HOWL · Werewolf Therapeutics, Inc.
$1.04
+0.06 (+6.12%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jul 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these condensed consolidated financial statements are issued in this Quarterly Report. We are currently evaluating strategies to raise additional capital, however, there can be no assurances that we will be successful in mitigating the conditions which raise substantial doubt about our ability to continue as a going concern in the near term, if at all.”View the 10-Q filed Jul 31, 2026
Market Cap
$47.63M
Shares
48.60M
Volume · Oct 19
378.85K
Avg daily vol (3M)
6.69M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.04
Open$0.98
Day$0.98–1.06
52W close$0.31–1.77
Avg vol 30d627K
Short int2.5M · 5.2% float · 3.7d
Short vol53%
DataApr 2021–Oct 2026
Filing10-Q · Jul 31
Up next
filed Jul 31, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$34.61M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$21.99M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.0%
Year over year · more shares
Price change (1Y)
-41.3%
Trailing year
Short interest
5.2%
Latest settlement · 3.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+57%
above
Price vs 50-day avg
+22%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
50%
mid-range
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+41%
trailing
YTD return
+64%
this year
Relative strength
+33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
2 of 46 funds reported for Sep 30 · net +113.4K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.17% of float · ▲ +47.2% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
46 holders — mid 3-yr range
Squeeze score
66
elevated · 0–100
Fundamentals
EPS growth
+18%
Y/Y
Free cash flow
$-60.3M
Balance sheet
$25.0M
net cash
Quant / Vol
risk profile
Volatility
143%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+57%
Bullish
Price vs 50-day avg
+22%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
50%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
2 of 46 funds reported for Sep 30 · net +113.4K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.17% of float · ▲ +47.2% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
46 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 50%
Range high $2
vs 200-day avg +57%
vs 50-day avg +22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HOWL
this stock
Werewolf Therapeutics, Inc.
|
$47.63M | +64.0% | — | — | 5.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.73B | +10.7% | +46.2% | 29.4 | 1.8% |
|
MRNA
Moderna, Inc.
|
$87.04B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.41B | +1.3% | +20.8% | 19.6 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HOWL | +5.9% | +6.1% | +40.5% | +12.8% | +64.0% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +7.4% | +7.0% | +32.8% | +12.3% | +51.6% |